Review



tumour cells u87  (SAS institute)


Bioz Verified Symbol SAS institute is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    SAS institute tumour cells u87
    Tumour Cells U87, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumour+cells+u87/u+87+cells/pmc05522274-164-3-6
    Average 90 stars, based on 1 article reviews
    tumour cells u87 - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth
    Article Snippet: Cultures of the tumour cells (U87, SAS and PC3, DU145) and HUVEC cells were described previously [ ].



    Similar Products

    94
    ATCC human u87 mg glioma brain tumour cells rodent 9l gliosarcoma brain tumour cells
    Fig. 4. (A) We further investigate the efficiency of SDT in the human glioblastoma <t>U87</t> rat model. The animal received three weekly treatments beginning from day 7. (B) The representative T1 contrast-enhanced MR images of control, FUS alone, 5-ALA alone, and SDT treatment. The first row in the SDT group demonstrated the long-term tumour-free survivor. The tumour disappeared after three treatments. However, SDT had a minimal impact on some animals, such as the second row in the SDT group. (C) The H&E stains stood for the animals from (B), respectively. (D) A significant difference was found in the third week between the control group and the SDT group. (E) The log-rank test showed prolonged survival in the SDT group, p = 0.01. (F) The body weight in all groups did not vary during three-week treatments.
    Human U87 Mg Glioma Brain Tumour Cells Rodent 9l Gliosarcoma Brain Tumour Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumour+cells+u87/9L%2FlacZ/pm39775160-184-4-17
    Average 94 stars, based on 1 article reviews
    human u87 mg glioma brain tumour cells rodent 9l gliosarcoma brain tumour cells - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    99
    ATCC tumour cell lines u87 mg
    Fig. 4. (A) We further investigate the efficiency of SDT in the human glioblastoma <t>U87</t> rat model. The animal received three weekly treatments beginning from day 7. (B) The representative T1 contrast-enhanced MR images of control, FUS alone, 5-ALA alone, and SDT treatment. The first row in the SDT group demonstrated the long-term tumour-free survivor. The tumour disappeared after three treatments. However, SDT had a minimal impact on some animals, such as the second row in the SDT group. (C) The H&E stains stood for the animals from (B), respectively. (D) A significant difference was found in the third week between the control group and the SDT group. (E) The log-rank test showed prolonged survival in the SDT group, p = 0.01. (F) The body weight in all groups did not vary during three-week treatments.
    Tumour Cell Lines U87 Mg, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumour+cells+u87/U-87+MG/pm37994101-242-8-42
    Average 99 stars, based on 1 article reviews
    tumour cell lines u87 mg - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    90
    SAS institute tumour cells u87
    Fig. 4. (A) We further investigate the efficiency of SDT in the human glioblastoma <t>U87</t> rat model. The animal received three weekly treatments beginning from day 7. (B) The representative T1 contrast-enhanced MR images of control, FUS alone, 5-ALA alone, and SDT treatment. The first row in the SDT group demonstrated the long-term tumour-free survivor. The tumour disappeared after three treatments. However, SDT had a minimal impact on some animals, such as the second row in the SDT group. (C) The H&E stains stood for the animals from (B), respectively. (D) A significant difference was found in the third week between the control group and the SDT group. (E) The log-rank test showed prolonged survival in the SDT group, p = 0.01. (F) The body weight in all groups did not vary during three-week treatments.
    Tumour Cells U87, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumour+cells+u87/u+87+cells/pmc05522274-164-3-6
    Average 90 stars, based on 1 article reviews
    tumour cells u87 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    99
    ATCC human tumour cell lines u87
    Fig. 4. (A) We further investigate the efficiency of SDT in the human glioblastoma <t>U87</t> rat model. The animal received three weekly treatments beginning from day 7. (B) The representative T1 contrast-enhanced MR images of control, FUS alone, 5-ALA alone, and SDT treatment. The first row in the SDT group demonstrated the long-term tumour-free survivor. The tumour disappeared after three treatments. However, SDT had a minimal impact on some animals, such as the second row in the SDT group. (C) The H&E stains stood for the animals from (B), respectively. (D) A significant difference was found in the third week between the control group and the SDT group. (E) The log-rank test showed prolonged survival in the SDT group, p = 0.01. (F) The body weight in all groups did not vary during three-week treatments.
    Human Tumour Cell Lines U87, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumour+cells+u87/U-87+MG/pm23291225-95-1-25
    Average 99 stars, based on 1 article reviews
    human tumour cell lines u87 - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    99
    ATCC human brain tumour cell line u87 mg
    Hsp90α expression in <t> U87-MG </t> post 17-AAG and sihsp90α treatment. The Hsp90α levels were deduced as the fraction of the observed Hsp90α levels in treated samples relative to the total Hsp90α levels in the untreated sample using immunofluorescence after 48 h and 72 h. Hsp90α expression analysis using immunofluorescence was performed by counting 150 cells. sihsp90α represent cells treated with hsp90α specific siRNA. sihsp90α + 17-AAG represent concurrent assays where the cells were treated with 17-AAG and sihsp90α for either 48 h or 72 h. This data is typical of three independent experiments. * p ≤ 0.05 and ** p ≤ 0.001 were considered statistically significant.
    Human Brain Tumour Cell Line U87 Mg, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumour+cells+u87/U-87+MG/pmc03763420-136-1-27
    Average 99 stars, based on 1 article reviews
    human brain tumour cell line u87 mg - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    Image Search Results


    Fig. 4. (A) We further investigate the efficiency of SDT in the human glioblastoma U87 rat model. The animal received three weekly treatments beginning from day 7. (B) The representative T1 contrast-enhanced MR images of control, FUS alone, 5-ALA alone, and SDT treatment. The first row in the SDT group demonstrated the long-term tumour-free survivor. The tumour disappeared after three treatments. However, SDT had a minimal impact on some animals, such as the second row in the SDT group. (C) The H&E stains stood for the animals from (B), respectively. (D) A significant difference was found in the third week between the control group and the SDT group. (E) The log-rank test showed prolonged survival in the SDT group, p = 0.01. (F) The body weight in all groups did not vary during three-week treatments.

    Journal: Scientific reports

    Article Title: Repeated 5-aminolevulinic acid mediated sonodynamic therapy using magnetic resonance guided focused ultrasound in rat brain tumour models.

    doi: 10.1038/s41598-025-85314-6

    Figure Lengend Snippet: Fig. 4. (A) We further investigate the efficiency of SDT in the human glioblastoma U87 rat model. The animal received three weekly treatments beginning from day 7. (B) The representative T1 contrast-enhanced MR images of control, FUS alone, 5-ALA alone, and SDT treatment. The first row in the SDT group demonstrated the long-term tumour-free survivor. The tumour disappeared after three treatments. However, SDT had a minimal impact on some animals, such as the second row in the SDT group. (C) The H&E stains stood for the animals from (B), respectively. (D) A significant difference was found in the third week between the control group and the SDT group. (E) The log-rank test showed prolonged survival in the SDT group, p = 0.01. (F) The body weight in all groups did not vary during three-week treatments.

    Article Snippet: Rodent 9L gliosarcoma and human U87 MG glioma brain tumour cells Rodent 9L gliosarcoma brain tumour cells (ATCC® CRL-2200TM) and human U87 MG glioblastoma (ATCC® HTB14TM) purchased from ATCC were cultured respectively in DMEM (Dulbecco’s modified Eagle’s medium) and EMEM (Eagle’s Minimum Essential Medium) and supplemented with 10% heat-inactivated fetal bovine serum (FBS) in 75 cm2 flasks in a 5% CO2-containing incubator at 37 °C.

    Techniques: Control

    Hsp90α expression in  U87-MG  post 17-AAG and sihsp90α treatment. The Hsp90α levels were deduced as the fraction of the observed Hsp90α levels in treated samples relative to the total Hsp90α levels in the untreated sample using immunofluorescence after 48 h and 72 h. Hsp90α expression analysis using immunofluorescence was performed by counting 150 cells. sihsp90α represent cells treated with hsp90α specific siRNA. sihsp90α + 17-AAG represent concurrent assays where the cells were treated with 17-AAG and sihsp90α for either 48 h or 72 h. This data is typical of three independent experiments. * p ≤ 0.05 and ** p ≤ 0.001 were considered statistically significant.

    Journal: Cancers

    Article Title: A Novel Therapeutic Strategy for the Treatment of Glioma, Combining Chemical and Molecular Targeting of Hsp90α

    doi: 10.3390/cancers3044228

    Figure Lengend Snippet: Hsp90α expression in U87-MG post 17-AAG and sihsp90α treatment. The Hsp90α levels were deduced as the fraction of the observed Hsp90α levels in treated samples relative to the total Hsp90α levels in the untreated sample using immunofluorescence after 48 h and 72 h. Hsp90α expression analysis using immunofluorescence was performed by counting 150 cells. sihsp90α represent cells treated with hsp90α specific siRNA. sihsp90α + 17-AAG represent concurrent assays where the cells were treated with 17-AAG and sihsp90α for either 48 h or 72 h. This data is typical of three independent experiments. * p ≤ 0.05 and ** p ≤ 0.001 were considered statistically significant.

    Article Snippet: The human brain tumour cell line U87-MG (glioblastoma multiforme) and human normal astrocyte cell line SVGp12 were purchased from European Collection of Cell Cultures (ECACC) and the American Type Culture Collection (ATCC), respectively.

    Techniques: Expressing, Immunofluorescence, Control